EC approves Sandoz ’s Rixathon for blood cancer and immunological diseases
Novartis division Sandoz ’s Rixathon (biosimilar rituximab) has received approval from the European Commission (EC) to treat blood cancers and immunological diseases in Europe.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news